SCHEMBL2806910

SCHEMBL2806910

C[Si](C)(C)C#Cc1ccc(NC(=O)O)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.44
MAPT P10636 1/20 0.44
PTK2 Q05397 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRA6 Q16445 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28449441 0.85 RAB9A (0.45) RAB9AMAPTPTK2MEN1KMT2A
SCHEMBL14840429 0.80 MAP4K1 (0.39) RAB9AMAPTPTK2MEN1KMT2A
SCHEMBL12403192 0.80 GABRA5 (0.45) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL18284273 0.80 RAB9A (0.42) RAB9AMAPTMEN1KMT2AL3MBTL1
SCHEMBL14784662 0.78 HTT (0.44) RAB9AL3MBTL1SMN1; SMN2TSHRNPC1
SCHEMBL503281 0.78 MTOR (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL25229723 0.78 RAB9A (0.40) RAB9AMEN1KMT2AGABRA1GABRG2
SCHEMBL483747 0.77 FGFR4 (0.48) RAB9AMAPTPTK2MEN1KMT2A
SCHEMBL3715011 0.77 MEN1 (0.58) RAB9AMAPTMEN1KMT2ATMPRSS4
SCHEMBL18135197 0.76 L3MBTL1 (0.55) RAB9AMEN1KMT2AL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411057-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2020-05-06 EP disclosed
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders LILLY CO ELI (US) 2013-11-14 US disclosed
US-8491869-B2 Imaging agents for detecting neurological disorders ELI LILLY AND COMPANY (US) 2013-07-23 US disclosed
WO-2010111303-A2 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-30 WO disclosed
US-20100239496-A1 Imaging agents for detecting neurological disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130302248-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 RAB9A 1055/4885MAPT 1/4885PTK2 3139/4885
US-20100239496-A1 Imaging agents for detecting neurological disorders MAPT, APP, PSEN1 RAB9A 1055/4885MAPT 1/4885PTK2 3139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.